← 研踪 PaperTrailarXiv:2611.12855 · v1
AI-based characterization of lymphoid structures and the tumor microenvironment reveals lower mature tertiary lymphoid structures, lymph-node follicles, and plasma cells after neoadjuvant therapy in lung squamous cell carcinoma
首次提交 2026-11-10 02:45
版本更新 2026-11-10 02:45
雷达观测 2026-11-10 15:22
摘要
Mature, germinal centre-bearing tertiary lymphoid structures (TLS) and mature lymph node follicles (secondary lymphoid structures, SLS) sustain the plasma cell response that shapes outcome and immunotherapy benefit in lung cancer. How this loco-regional axis differs between neoadjuvant-treated and therapy-naive tumors is poorly defined. We analyzed H&E whole-slide images of resected tumors and paired proximal and distal lymph nodes from matched neoadjuvant-treated (neoLUSC, n=20) and therapy-naive (naivLUSC, n=20) lung squamous cell carcinoma (LUSC) patients. Aignostics Atlas H&E Tissue Analysis (HETA) models quantified cell densities per tissue compartment and cell-cell co-localization; a dedicated deep-learning model validated against pathologist annotations detected TLS and SLS and graded their maturity. Prognostic value was tested in an independent cohort (n=458; 46 treated). In neoLUSC tumors, stromal plasma cell density was 72% (p=0.004) and stromal lymphocyte density 48% (p=0.015) lower than in naivLUSC; macrophages and granulocytes did not differ significantly. Total and immature TLS did not differ, whereas mature TLS in the tumor (p=0.034) and mature SLS in the tumor-distal lymph node (p=0.003) were lower in neoLUSC patients. Peri-TLS plasma cell density correlated with tumor lymphocyte density in naivLUSC (rho=0.54, p=0.017) but not in neoLUSC tumors (rho=0.07). In the validation cohort, stromal plasma cell density (HR 0.69, p=0.011) and lymphocyte-plasma cell co-localization (HR 0.66, p=0.004) were associated with longer survival, and neoadjuvant status with shorter survival (HR 1.50, p=0.026). Neoadjuvant therapy is thus associated with fewer mature lymphoid structures and weaker coupling of the humoral compartment to the tumor rather than uniformly lower immune readouts. The stromal plasma cell/co-localization axis is a candidate prognostic biomarker.
观测到的版本
相邻记录可能跳过中间版本；首次发现 v2 及以上也会标为版本更新。
v1 · 2026-11-10 02:45 · 最新观测版本
AI-based characterization of lymphoid structures and the tumor microenvironment reveals lower mature tertiary lymphoid structures, lymph-node follicles, and plasma cells after neoadjuvant therapy in lung squamous cell carcinoma
Mature, germinal centre-bearing tertiary lymphoid structures (TLS) and mature lymph node follicles (secondary lymphoid structures, SLS) sustain the plasma cell response that shapes outcome and immunotherapy benefit in lung cancer. How this loco-regional axis differs between neoadjuvant-treated and therapy-naive tumors is poorly defined. We analyzed H&E whole-slide images of resected tumors and paired proximal and distal lymph nodes from matched neoadjuvant-treated (neoLUSC, n=20) and therapy-naive (naivLUSC, n=20) lung squamous cell carcinoma (LUSC) patients. Aignostics Atlas H&E Tissue Analysis (HETA) models quantified cell densities per tissue compartment and cell-cell co-localization; a dedicated deep-learning model validated against pathologist annotations detected TLS and SLS and graded their maturity. Prognostic value was tested in an independent cohort (n=458; 46 treated). In neoLUSC tumors, stromal plasma cell density was 72% (p=0.004) and stromal lymphocyte density 48% (p=0.015) lower than in naivLUSC; macrophages and granulocytes did not differ significantly. Total and immature TLS did not differ, whereas mature TLS in the tumor (p=0.034) and mature SLS in the tumor-distal lymph node (p=0.003) were lower in neoLUSC patients. Peri-TLS plasma cell density correlated with tumor lymphocyte density in naivLUSC (rho=0.54, p=0.017) but not in neoLUSC tumors (rho=0.07). In the validation cohort, stromal plasma cell density (HR 0.69, p=0.011) and lymphocyte-plasma cell co-localization (HR 0.66, p=0.004) were associated with longer survival, and neoadjuvant status with shorter survival (HR 1.50, p=0.026). Neoadjuvant therapy is thus associated with fewer mature lymphoid structures and weaker coupling of the humoral compartment to the tumor rather than uniformly lower immune readouts. The stromal plasma cell/co-localization axis is a candidate prognostic biomarker.
查看此版本解读 →查看此版本原文 ↗